<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01756885</url>
  </required_header>
  <id_info>
    <org_study_id>R01CA165001</org_study_id>
    <nct_id>NCT01756885</nct_id>
    <nct_alias>NCT02851901</nct_alias>
  </id_info>
  <brief_title>Extended Varenicline Treatment for Smoking Among Cancer Patients</brief_title>
  <official_title>Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Upwards of 33-50% of cancer patients who smoked prior to diagnosis continue to smoke
      following diagnosis and treatment. With medical advances in cancer care yielding a growing
      constituency of cancer survivors, addressing nicotine dependence in this population is a
      priority. While PHS guidelines recommend acute treatment durations with approved medications
      for tobacco use, extending the duration of treatment beyond the standard treatment duration
      significantly increases quit rates, reduces the risk for a relapse, and promotes recovery to
      abstinence following a lapse. Varenicline may be particularly effective for cancer patients
      given the drug's beneficial effects on affect and cognition. In this trial, 374 cancer
      patients will be randomized to standard varenicline treatment (12 weeks active + 12 weeks
      placebo) or extended varenicline treatment (24 weeks active). The investigators hypothesize
      that 1) Extended varenicline therapy will increase 24- and 52-week biochemically-confirmed
      abstinence versus standard varenicline treatment, 2) Quality of life will be rated higher in
      the extended therapy group versus the standard therapy group, and there will be no
      significant differences between groups in terms of severe side effects, and 3) Improved
      affect and reduced cognitive impairment will mediate the effect of extended therapy on quit
      rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND

      Prevalence of Smoking among Cancer Patients

      The rate of smoking among individuals with cancer who are age 40 or under are substantially
      higher (38-40%) than rates of smoking in the comparable age group in the general population
      (~26%; Bellizzi et al., 2005; Coups &amp; Ostroff, 2005). Studies with patients that have
      traditional tobacco-related cancers show extremely high rates of smoking; upwards of 50% of
      head and neck (Duffy et al., 2008) and lung (Cooley et al., 2009) cancer patients report
      current smoking. However, high rates of smoking are not unique to such traditional
      tobacco-related disease sites. Significant rates of current smoking have been reported among
      testicular (19%; Shinn et al., 2007), prostate (16-17%; Gong et al., 2008; Pantarotto et al.,
      2007), cervical (21%; Beesley et al., 2008), breast (19%; Li et al., 2009), bladder (18%;
      Blanchard et al., 2008), esophageal (39%; Sundelof et al., 2008), colorectal (22%; Vincenzi
      et al., 2009), and lymphoma (19%; Geyer et al., 2010) cancer patients. Overall, about
      one-third to one-half of cancer patients who were smokers prior to their diagnosis continue
      to smoke following diagnosis (Gritz et al., 2006).

      Adverse Health Consequences of Smoking among Individuals with Cancer

      Continued smoking by cancer patients has been associated with diminished QOL, reduced
      survival probability and duration, and increased risk for disease recurrence and a second
      primary tumor (Gritz et al., 2006; 2007). Continued smoking by cancer patients is associated
      with greater treatment side effects or diminished QOL among head and neck (Duffy et al.,
      2007; Zevallos et al., 2009), lung (Daniel et al., 2009), prostate (Ku et al., 2009), and a
      heterogeneous group of (Schnoll et al., 2010a) cancer patients. A recent meta-analysis of
      studies with lung cancer patients found that continued smoking was associated with an
      increased risk of death, recurrence, and a second primary tumor (Parsons et al., 2010).
      Likewise, studies with head and neck cancer patients have reported that patients who continue
      to smoke following their diagnosis have a lower survival rate and an increased risk for a
      recurrence and a second primary tumor (Browman et al., 2002; Hilgert et al., 2009; Fortin et
      al., 2009; Leon et al., 2009). Continued smoking has also been associated with reduced
      survival among breast (Aksoy et al., 2007), lymphoma (Geyer et al., 2010), esophageal
      (Sundelof et al., 2008), prostate (Gong et al., 2008), cervical (Coker et al., 2009), and
      bladder (Aveyard et al., 2002) cancer patients and with an increased risk of recurrence or a
      second primary tumor among bladder (Fleshner et al., 1999), breast (Li et al., 2009),
      lymphoma (Moser et al., 2006), and colorectal (Jacobson et al., 1994) cancer patients.
      Continued smoking may worsen prognosis by reducing the effectiveness of chemotherapy (Duarte
      et al., 2008; van der Bol et al., 2007; Vincenzi et al., 2009; Hotta et al., 2008) and
      radiotherapy (Browman et al., 1993).

      Nicotine Dependence Treatments for Those with Cancer

      Very few smoking cessation trials have been conducted with this population (Gritz et al.,
      2006; 2007) and many of these past trials have used small samples and relied on self-report
      for smoking abstinence outcomes (de Moor et al., 2008). After nearly two decades of research
      in this area, not a single smoking cessation randomized clinical trial has yielded
      significant treatment effects (excluding Emmons et al., 2009, which studied adult survivors
      of childhood cancer; de Moor et al., 2008). Nurse-led (Griebel et al., 1998; Stanislaw &amp;
      Wewers, 1994; Wewers et al., 1994), physician-led (Browning et al., 2000; Gritz et al., 1993;
      Schnoll et al., 2003b), and behavioral (Schnoll et al., 2005; Wakefield et al., 2004) smoking
      cessation trials have failed to yield treatment effects for cancer patients. Our recent
      clinical trial with bupropion (Schnoll et al., 2010a) found no main effect for the
      medication, but bupropion increased abstinence rates, reduced withdrawal symptoms, and
      improved QOL more for patients with depression, vs. those without depression. Lastly, a very
      recent varenicline study reported end-of-treatment quit rates of 34%, vs. 14% for the
      comparison group (OR = 3.14), and a side effect profile that mirrored the general population
      (Park et al., 2011). While these data are encouraging, as were reported feasibility data, the
      study was under-powered (n = 49) and did not use a randomized design. Thus, there is
      currently no empirically-based treatment model for addressing nicotine dependence in the
      oncologic context. As such, a recent NCI meeting, with representatives from NCI cancer
      centers, concluded that the evaluation of novel smoking cessation interventions for cancer
      patients is a critical priority (Morgan et al., 2010).

      A Novel Treatment for Cancer Patients who Smoke: Extended Duration Varenicline Thus, nicotine
      dependence treatments for cancer patients may show greater efficacy if they adequately
      address the patient's relatively high level of nicotine dependence, risk for psychological
      distress and cognitive impairment, and delayed relapse process. We hypothesize that extended
      duration varenicline (24-weeks) will address these barriers to cessation and significantly
      increase quit rates, vs. standard varenicline treatment (12 weeks).

      Our rationale for selecting varenicline is as follows. First, the high rate of nicotine
      dependence among cancer patients underscores the need to include a pharmacotherapy as part of
      treatment. Varenicline is currently the most efficacious FDA-approved medication for nicotine
      dependence, yielding quit rates that significantly exceed those produced by bupropion
      (Gonzales et al., 2006; Jorenby et al., 2006) and nicotine patch (Aubin et al., 2008; Biazzo
      et al., 2010; Stapleton et al., 2008). Second, varenicline mitigates adverse psychological
      effects and cognitive impairment associated with quitting smoking (Patterson et al., 2009;
      Smith et al., 2009; Philip et al., 2009; Rollema et al., 2009; Sofuoglu et al., 2009). The
      anti-depressant-like (Rollema et al., 2009) and cognitive enhancing (Loughead et al., 2010)
      effects of varenicline is consistent with what we know about how varenicline works. As a
      nicotinic acetylcholine receptor (nAChRs) partial agonist, varenicline binds to nAChRs and
      blocks the entry of nicotine (from smoking) into the receptor and stimulates a moderate
      release of dopamine. This reduces the rewarding effects of smoking and reduces withdrawal
      symptoms (Rollema et al., 2009). Preclinical studies also indicate that α4β2 nAChRs subtypes
      are critical for cognition (Levin et al., 2006) and stimulation of these receptors by
      varenicline yields improved cognitive function (Loughead et al., 2010). Likewise, animal
      studies indicate that the simultaneous activation and desensitization of nAChRs receptors
      produced by nicotinic partial agonists like varenicline can yield antidepressant-like effects
      (Mineur &amp; Picciotto, 2010), which underlies current evaluations of varenicline as a treatment
      for major depression. Third, varenicline is efficacious and safe for treating nicotine
      dependence among various clinical populations, including: cardiovascular disease patients
      (Rigotti et al., 2010), COPD patients (Tashkin et al., 2010), smokers with comorbid alcohol
      (Hays et al., 2010) and cocaine (Poling et al., 2010) dependence, and smokers with comorbid
      affective or psychotic disorders (McClure et al., 2010; Smith et al., 2009; Philip et al.,
      2009). It has been shown to be safe when taken over 52 weeks (Williams et al., 2007).
      Although there have been reports of adverse psychiatric events following varenicline use,
      leading the FDA to mandate a boxed warning for varenicline, pooled data from controlled
      efficacy trials (Cahill et al., 2009; Tonstad et al., 2010), effectiveness trials (McClure et
      al., 2010), and large cohort studies (Gunnell et al., 2009; Kasliwal et al., 2009)
      demonstrate that varenicline is safe for treating nicotine dependence, even among smokers
      with psychiatric comorbidity, including depression (Stapleton et al., 2008; McClure et al.,
      2010; Steinberg et al., 2010).

      Our rationale for selecting an extended duration treatment is as follows. First, we have
      shown, in a placebo-controlled randomized trial with general population smokers, that
      24-weeks of transdermal nicotine, vs. the standard 8-weeks, increases 6-month quit rates by
      an OR of 1.81 (32% vs. 20%; Schnoll et al., 2010b). Second, and importantly, extending
      treatment with the nicotine patch to 24-weeks significantly helps smokers with high levels of
      nicotine dependence and cognitive impairment, in particular, to overcome their liability to
      relapse (see below). While extended therapy with transdermal nicotine did not offset the
      effect of depression symptoms on relapse rates, the quit rate among depressed smokers in
      extended treatment was almost 2-times higher than it was for depressed smokers in standard
      treatment (see below). Third, we showed in our placebo-controlled randomized clinical trial
      with general population smokers (Schnoll et al., 2010b) that extending treatment with
      transdermal nicotine to 24-weeks (vs. 8-weeks) significantly reduced the probability that
      smokers would experience a lapse and, importantly, increased the likelihood that smokers
      would recover to abstinence following a lapse. Extended duration treatment offered smokers
      who lapsed the opportunity to re-start their quit attempt and eventually achieve abstinence.
      Thus, extended duration varenicline may be particularly efficacious at addressing the
      barriers to cessation that are evident among cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">May 31, 2018</completion_date>
  <primary_completion_date type="Actual">May 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>7-day CO-verified Tobacco Abstinence</measure>
    <time_frame>Weeks 24 &amp; 52</time_frame>
    <description>Number of Participants with Verified 7 Day Tobacco Abstinence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life at Week 24 and 52</measure>
    <time_frame>Weeks 24 &amp; 52</time_frame>
    <description>The Short-Form Health Survey (SF-12) assesses Quality of Life (QOL). Scale range from 12 - 47. Higher score indicates worse quality of life.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Continuous Abstinence</measure>
    <time_frame>Weeks 12, 24, and 52</time_frame>
    <description>No smoking from baseline to time-point, after a 2-week grace period.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">207</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Standard Varenicline Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 weeks of active varenicline + 12 weeks of placebo + smoking cessation counseling
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
Days 85-168: Placebo - 1.0mg twice daily orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended Varenicline Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 weeks of active varenicline + smoking cessation counseling
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-168: 1.0mg twice daily orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Varenicline was used in accordance with FDA approved labeling: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).</description>
    <arm_group_label>Extended Varenicline Treatment</arm_group_label>
    <arm_group_label>Standard Varenicline Treatment</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>On Day 85, participants randomized to standard therapy will be given placebo pills (resembling the 1.0mg pills),</description>
    <arm_group_label>Standard Varenicline Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Smoking Cessation Counseling</intervention_name>
    <description>Behavioral Counseling (from Week 0 - Week 18)
The counseling protocol was based on PHS guidelines for smoking cessation treatment (Fiore et al., 2008), used in our past studies with cancer patients (Schnoll et al., 2010a) and in our ongoing cessation trial at NU (R01 DA025078). Counseling is included given its efficacy at helping smokers quit (Fiore et al., 2008) and to increase study retention. Counseling is provided to both treatment arms through Week 18 to equate for time and attention across arms and since this method was used in varenicline clinical trials (Gonzales et al., 2006) and in our extended therapy trial (Schnoll et al., 2010b). In-person counseling was selected for most sessions to ensure adequate monitoring of participant safety and adherence throughout the trial.</description>
    <arm_group_label>Extended Varenicline Treatment</arm_group_label>
    <arm_group_label>Standard Varenicline Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older who self-report smoking at least 5 cigarettes (menthol and
             non-menthol) per day, on average, for the last 6 months.

          2. Current cancer diagnosis (all sites) or diagnosis within the past 5 years.

          3. Karnofsky Score of &gt;50 or ECOG Performance Status score of &lt;2 within 6 months of
             enrollment.

          4. Able to use varenicline safely, based on a medical evaluation including medical
             history and physical examination, and psychiatric evaluation.

          5. Residing in the geographic area for at least 12 months.

          6. Women of childbearing potential (based on medical history and physical exam) must
             consent to use a medically accepted method of birth control (e.g., condoms and
             spermicide, oral contraceptive, Depo-Provera injection, contraceptive patch, tubal
             ligation) or abstain from sexual intercourse during the time they are taking study
             medication and for at least one month after the medication period ends.

          7. Able to communicate fluently in English.

          8. Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the combined consent/HIPAA form.

        Exclusion Criteria:

        Smoking Behavior

          1. Current enrollment or plans to enroll in another smoking cessation program in the next
             12 months.

          2. Regular (daily) use of chewing tobacco, snuff, snus, cigars, cigarillos, or pipes.

          3. Current use or plans to use nicotine substitutes (gum, patch, lozenge, e-cigarette) or
             smoking cessation treatments in the next 12 months.

               1. Note: Once participants are found eligible for the study, they are told they
                  should refrain from using any nicotine replacement therapy (NRT) for the duration
                  of the study. If a subject reports an isolated (non-daily) instance of NRT use
                  during the study, they may be permitted to continue.

        Alcohol/Drug Exclusion Criteria

          1. Diagnosis of substance abuse or dependence that has been unstable in the past year.

          2. Positive urine drug screen (for cocaine, opioids, or methamphetamines) at the Intake
             Session (unless taking opiate for pain management).

          3. Breath Alcohol Concentration (BrAC) assessment greater than or equal to 0.01 at the
             Intake Session.

          4. Current alcohol consumption that exceeds 25 standard alcoholic drinks/week.

        Medication Exclusion Criteria

        Current use or recent discontinuation (within last 14 days) of the following medications:

          1. Other smoking cessation medications (e.g. Zyban, Wellbutrin, Wellbutrin SR, Chantix)

             a. Note: Once participants are found eligible for the study, they are instructed to
             only use the smoking cessation medication provided to them by the study staff. If a
             subject reports an isolated (non-daily) instance of using a non-study smoking
             cessation medication, the study physician and PI will evaluate the situation and
             determine if it is safe for the subject to continue participation.

          2. Anti-psychotic medications.

          3. Bipolar Disorder medications.

        Medical Exclusion Criteria

          1. Women who are pregnant, planning a pregnancy within the next 12 months, or lactating.

          2. History of epilepsy or seizure disorder (history of seizure requires Study Physician
             approval).

          3. History of kidney disease, including transplant.

          4. Uncontrolled hypertension (SBP &gt;160 or DBP &gt;100).

             a. Note: If a participant presents with blood pressure greater than 160/100 at
             sessions occurring on Week 0 (Pre-Quit) or at any other point during the treatment
             period, they will not be provided with/able to continue on medication unless the study
             physician grants approval.

          5. History of heart disease, stroke or MI, unstable angina, abnormal heart rhythms, or
             tachycardia (if stable, requires Study Physician approval).

          6. Abnormal ECG (unless approved by Study Physician).

          7. Any suicide risk score on MINI, current suicidal ideation on Columbia scale, or
             self-reported suicide attempt.

          8. Current or past diagnosis of psychotic or bipolar disorder, as determined by
             self-report &amp; MINI.

          9. Current diagnosis of unstable and untreated major depression, as determined by
             self-report &amp; MINI (eligible if stable for &gt;30 days).

         10. Previous allergic reaction to varenicline.

        General Exclusion Criteria

          1. Any medical condition or concomitant medication that could compromise subject safety
             or treatment, as determined by the Principal Investigator and/or Study Physician.

          2. Inability to provide informed consent or complete any of the study tasks as determined
             by the Principal Investigator and/or Study Physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Schnoll, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>December 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2012</study_first_posted>
  <results_first_submitted>April 19, 2019</results_first_submitted>
  <results_first_submitted_qc>May 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2019</results_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking cessation</keyword>
  <keyword>Nicotine dependence</keyword>
  <keyword>Varenicline</keyword>
  <keyword>Chantix</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT01756885/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Varenicline Treatment</title>
          <description>12 weeks of active varenicline + 12 weeks of placebo + smoking cessation counseling
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
Days 85-168: Placebo - 1.0mg twice daily orally
Varenicline
Placebo
Smoking Cessation Counseling</description>
        </group>
        <group group_id="P2">
          <title>Extended Varenicline Treatment</title>
          <description>24 weeks of active varenicline + smoking cessation counseling
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-168: 1.0mg twice daily orally
Varenicline
Smoking Cessation Counseling</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Varenicline Treatment</title>
          <description>12 weeks of active varenicline + 12 weeks of placebo + smoking cessation counseling
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
Days 85-168: Placebo - 1.0mg twice daily orally
Varenicline
Placebo
Smoking Cessation Counseling</description>
        </group>
        <group group_id="B2">
          <title>Extended Varenicline Treatment</title>
          <description>24 weeks of active varenicline + smoking cessation counseling
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-168: 1.0mg twice daily orally
Varenicline
Smoking Cessation Counseling</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
            <count group_id="B2" value="105"/>
            <count group_id="B3" value="207"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" spread="9.5"/>
                    <measurement group_id="B2" value="58.00" spread="9.4"/>
                    <measurement group_id="B3" value="58.5" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fagerström Test for Nicotine Dependence</title>
          <description>Scale range from 0-10. Higher score indicates greater nicotine dependence.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.6" spread="2.2"/>
                    <measurement group_id="B2" value="4.4" spread="2.1"/>
                    <measurement group_id="B3" value="4.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Score</title>
          <description>The Karnofsky Performance Scale is an assessment tool for functional impairment. Scale range from 0-100. Higher score indicates less functional impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.7" spread="11.7"/>
                    <measurement group_id="B2" value="92.1" spread="10.9"/>
                    <measurement group_id="B3" value="91.9" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status</title>
          <description>The ECOG Performance Scale is used to assess how a patient's cancer is progressing and assess how the disease affects the daily living abilities of the patient. Scale range from 0-5. Higher score indicates further progression of cancer.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.25" spread="0.43"/>
                    <measurement group_id="B2" value="0.25" spread="0.44"/>
                    <measurement group_id="B3" value="0.25" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Breath carbon monoxide</title>
          <description>Breath carbon monoxide is the level of carbon monoxide in a person's exhalation. The minimum score is 0, while there is no maximum score. Higher scores indicate a higher level of carbon monoxide in parts per million (ppm) in breath.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.2" spread="11.3"/>
                    <measurement group_id="B2" value="19.7" spread="11.0"/>
                    <measurement group_id="B3" value="19.0" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>7-day CO-verified Tobacco Abstinence</title>
        <description>Number of Participants with Verified 7 Day Tobacco Abstinence.</description>
        <time_frame>Weeks 24 &amp; 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Varenicline Treatment</title>
            <description>12 weeks of active varenicline + 12 weeks of placebo + smoking cessation counseling
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
Days 85-168: Placebo - 1.0mg twice daily orally
Varenicline
Placebo
Smoking Cessation Counseling</description>
          </group>
          <group group_id="O2">
            <title>Extended Varenicline Treatment</title>
            <description>24 weeks of active varenicline + smoking cessation counseling
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-168: 1.0mg twice daily orally
Varenicline
Smoking Cessation Counseling</description>
          </group>
        </group_list>
        <measure>
          <title>7-day CO-verified Tobacco Abstinence</title>
          <description>Number of Participants with Verified 7 Day Tobacco Abstinence.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life at Week 24 and 52</title>
        <description>The Short-Form Health Survey (SF-12) assesses Quality of Life (QOL). Scale range from 12 - 47. Higher score indicates worse quality of life.</description>
        <time_frame>Weeks 24 &amp; 52</time_frame>
        <population>Difference in number of participants at Weeks 24 and 52 are due to attrition.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Varenicline Treatment</title>
            <description>12 weeks of active varenicline + 12 weeks of placebo + smoking cessation counseling
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
Days 85-168: Placebo - 1.0mg twice daily orally
Varenicline
Placebo
Smoking Cessation Counseling</description>
          </group>
          <group group_id="O2">
            <title>Extended Varenicline Treatment</title>
            <description>24 weeks of active varenicline + smoking cessation counseling
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-168: 1.0mg twice daily orally
Varenicline
Smoking Cessation Counseling</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life at Week 24 and 52</title>
          <description>The Short-Form Health Survey (SF-12) assesses Quality of Life (QOL). Scale range from 12 - 47. Higher score indicates worse quality of life.</description>
          <population>Difference in number of participants at Weeks 24 and 52 are due to attrition.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.75" spread="6.17"/>
                    <measurement group_id="O2" value="38.46" spread="5.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.06" spread="6.81"/>
                    <measurement group_id="O2" value="36.91" spread="6.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Continuous Abstinence</title>
        <description>No smoking from baseline to time-point, after a 2-week grace period.</description>
        <time_frame>Weeks 12, 24, and 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Varenicline Treatment</title>
            <description>12 weeks of active varenicline + 12 weeks of placebo + smoking cessation counseling
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
Days 85-168: Placebo - 1.0mg twice daily orally
Varenicline
Placebo
Smoking Cessation Counseling</description>
          </group>
          <group group_id="O2">
            <title>Extended Varenicline Treatment</title>
            <description>24 weeks of active varenicline + smoking cessation counseling
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-168: 1.0mg twice daily orally
Varenicline
Smoking Cessation Counseling</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Continuous Abstinence</title>
          <description>No smoking from baseline to time-point, after a 2-week grace period.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>53 weeks</time_frame>
      <desc>Research staff member completed side effect assessments and determined the severity of the adverse events; the relationship of the event to the study drug and the decision on the course of action for the participant was decided by the site physicians and psychologists after review of the report. Participants were monitored for the development of adverse events by assessing side effects at each assessment time-point, as well as through open-ended questions during assessments.</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard Varenicline Treatment</title>
          <description>12 weeks of active varenicline + 12 weeks of placebo + smoking cessation counseling
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
Days 85-168: Placebo - 1.0mg twice daily orally
Varenicline
Placebo
Smoking Cessation Counseling</description>
        </group>
        <group group_id="E2">
          <title>Extended Varenicline Treatment</title>
          <description>24 weeks of active varenicline + smoking cessation counseling
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-168: 1.0mg twice daily orally
Varenicline
Smoking Cessation Counseling</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Constipation and bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Facial edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Fever and swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Enterocolotis infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pelvic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radiation burn infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cracked ribs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Injury from fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration, fluid build-up</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Second cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cancer progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety (panic) attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatic obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia and difficulty breathing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>High cholesterol</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea, abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cholecytstosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Gout (worsening)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pins and needles feeling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Fainting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer recurrence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Bracial plexopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Suicidality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hostility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Asthma attack</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin swelling, rash, or redness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert Schnoll</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-746-7143</phone>
      <email>schnoll@pennmedicine.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

